KR20190040302A - 글루타미나제 억제제와의 병용 요법 - Google Patents

글루타미나제 억제제와의 병용 요법 Download PDF

Info

Publication number
KR20190040302A
KR20190040302A KR1020197008262A KR20197008262A KR20190040302A KR 20190040302 A KR20190040302 A KR 20190040302A KR 1020197008262 A KR1020197008262 A KR 1020197008262A KR 20197008262 A KR20197008262 A KR 20197008262A KR 20190040302 A KR20190040302 A KR 20190040302A
Authority
KR
South Korea
Prior art keywords
cancer
substituted
alkyl
arylalkyl
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020197008262A
Other languages
English (en)
Korean (ko)
Inventor
프란세스코 파라티
케이스 오르포드
샘 에이치 화이팅
Original Assignee
칼리테라 바이오사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 칼리테라 바이오사이언시즈, 인코포레이티드 filed Critical 칼리테라 바이오사이언시즈, 인코포레이티드
Publication of KR20190040302A publication Critical patent/KR20190040302A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197008262A 2016-08-25 2017-08-25 글루타미나제 억제제와의 병용 요법 Withdrawn KR20190040302A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379604P 2016-08-25 2016-08-25
US62/379,604 2016-08-25
PCT/US2017/048581 WO2018039544A1 (en) 2016-08-25 2017-08-25 Combination therapy with glutaminase inhibitors

Publications (1)

Publication Number Publication Date
KR20190040302A true KR20190040302A (ko) 2019-04-17

Family

ID=61240223

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197008262A Withdrawn KR20190040302A (ko) 2016-08-25 2017-08-25 글루타미나제 억제제와의 병용 요법

Country Status (12)

Country Link
US (2) US10278968B2 (enExample)
EP (1) EP3503886A4 (enExample)
JP (1) JP2019526560A (enExample)
KR (1) KR20190040302A (enExample)
CN (1) CN110139649A (enExample)
AU (1) AU2017315446A1 (enExample)
BR (1) BR112019003533A2 (enExample)
CA (1) CA3034890A1 (enExample)
EA (1) EA201990567A1 (enExample)
MX (1) MX2019002108A (enExample)
SG (1) SG11201901389XA (enExample)
WO (1) WO2018039544A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023277502A1 (ko) * 2021-06-28 2023-01-05 연세대학교 산학협력단 암의 예방 또는 치료용 약학 조성물

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62447B1 (sr) 2012-11-16 2021-11-30 Calithera Biosciences Inc Heterociklični inhibitori glutaminaze
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
EA035354B1 (ru) 2015-04-06 2020-06-01 Калитера Байосайенсиз, Инк. Лечение рака легких ингибиторами глутаминазы
EP3359150A4 (en) 2015-10-05 2019-11-06 Calithera Biosciences, Inc. COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS AND IMMUNO-ONCOLOGICAL AGENTS
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
WO2022177983A1 (en) * 2021-02-19 2022-08-25 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
WO2002076939A2 (en) 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
EP1747282B1 (en) 2004-04-15 2011-06-08 University of Florida Research Foundation, Inc. Map-2 proteolytic breakdown products as diagnostic biomarkers for neural injury
EP2255818B1 (en) 2008-02-19 2018-08-22 Earnest Medicine Co., Ltd. Oral or enteral composition useful for recovery of physical functions
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
WO2012006506A1 (en) 2010-07-09 2012-01-12 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
EP2640189A4 (en) 2010-11-18 2014-03-19 Deuteria Pharmaceuticals Inc 3-deutero-pomalidomide
CN103030597B (zh) 2011-09-30 2014-10-01 南昌滨西科技有限公司 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途
WO2013078123A1 (en) 2011-11-21 2013-05-30 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
WO2014039960A1 (en) 2012-09-10 2014-03-13 Celgene Corporation Methods for the treatment of locally advanced breast cancer
RS62447B1 (sr) * 2012-11-16 2021-11-30 Calithera Biosciences Inc Heterociklični inhibitori glutaminaze
EP2922832B1 (en) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminase inhibitors and methods of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) * 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CA2892817A1 (en) 2012-12-03 2014-06-12 Calithera Biosciences Inc. Treatment of cancer with heterocyclic inhibitors of glutaminase
TWI660739B (zh) 2013-10-25 2019-06-01 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US10221459B2 (en) 2014-05-13 2019-03-05 Case Western Reserve University Compositions and methods of treating cancer harboring PIKC3A mutations
KR20170012562A (ko) 2014-06-13 2017-02-02 칼리테라 바이오사이언시즈 인코포레이티드 글루타미나제 억제제를 사용하는 병용 요법
WO2016004418A1 (en) 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Glutaminase inhibitor therapy
WO2016014890A1 (en) 2014-07-24 2016-01-28 Calithera Biosciences, Inc. Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
US10316030B2 (en) 2014-08-07 2019-06-11 Calithera Biosciences, Inc. Crystal forms of glutaminase inhibitors
WO2016054388A1 (en) 2014-10-03 2016-04-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Glutaminase inhibitors
WO2016077632A2 (en) * 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications
MX379263B (es) 2015-03-30 2025-03-11 Calithera Biosciences Inc Uso de inhibidores de glutaminasa para el tratamiento o prevención de cáncer.
EA035354B1 (ru) 2015-04-06 2020-06-01 Калитера Байосайенсиз, Инк. Лечение рака легких ингибиторами глутаминазы
JP2019524852A (ja) 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ， インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
US20180055825A1 (en) 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
SG11201901389XA (en) 2016-08-25 2019-03-28 Calithera Biosciences Inc Combination therapy with glutaminase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023277502A1 (ko) * 2021-06-28 2023-01-05 연세대학교 산학협력단 암의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
CA3034890A1 (en) 2018-03-01
SG11201901389XA (en) 2019-03-28
US20190275038A1 (en) 2019-09-12
AU2017315446A1 (en) 2019-03-07
US10278968B2 (en) 2019-05-07
US20180055843A1 (en) 2018-03-01
EP3503886A1 (en) 2019-07-03
EP3503886A4 (en) 2020-07-22
BR112019003533A2 (pt) 2019-05-21
WO2018039544A1 (en) 2018-03-01
CN110139649A (zh) 2019-08-16
JP2019526560A (ja) 2019-09-19
EA201990567A1 (ru) 2019-08-30
MX2019002108A (es) 2019-07-08

Similar Documents

Publication Publication Date Title
KR20170012562A (ko) 글루타미나제 억제제를 사용하는 병용 요법
US10905701B2 (en) Compositions and methods for inhibiting arginase activity
KR20190040302A (ko) 글루타미나제 억제제와의 병용 요법
JP2020510032A (ja) グルタミナーゼ阻害剤との併用療法
JP6971239B2 (ja) グルタミナーゼ阻害剤とイムノオンコロジー薬剤との併用療法
EP3116872A1 (en) Combination therapy with glutaminase inhibitors
WO2016014890A1 (en) Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase
CN109982703A (zh) 用谷氨酰胺酶抑制剂的组合疗法
HK40010184A (en) Combination therapy with glutaminase inhibitors
HK40020656A (en) Combination therapy with glutaminase inhibitors
HK1241274B (zh) 用谷氨酰胺酶抑制剂的组合疗法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190321

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200821

Comment text: Request for Examination of Application

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20210830

WITB Written withdrawal of application